O varian cancer (OC), principally its most common histotype, highgrade serous ovarian carcinoma (HGSC), is the leading cause of death from gynecologic cancers. OC is responsible for 4271 deaths per year in the United Kingdom, 42,700 deaths per year in Europe, 14,240 deaths per year in the United States, and 152,000 deaths per year worldwide. 1, 2 Despite advances in treatment, there have been only marginal improvements in survival over the last 20 years. 3 Screening for this disease has not yet been shown to reduce the mortality rate, 4 which leads to a drive for exploring newer prevention strategies.
There is increasing evidence that the fallopian tube plays a central role in the origin of HGSC [5] [6] [7] [8] [9] and serous tubal intraepithelial carcinoma (STIC) is established as a precursor lesion when it is present as a continuum with early tubal carcinomas that support transition from in situ to invasive cancer. 10 We too have previously seen HGSC that involved fimbrial tissue on the ovarian surface ( Figure 1 ). The growing evidence in favor of tubal origin of epithelial OC has led to opportunistic bilateral salpingectomy (OBS) being recommended as an OC prevention strategy for premenopausal women who have completed their family and are undergoing tubal sterilization or other benign gynecologic surgery. 9 Tubal ligation and hysterectomy are associated with a reduction in OC risk. 11 Supporting evidence for salpingectomy also comes from a 35e42% reduction in OC risk reported on a retrospective analysis of Swedish 12 and Danish 13 populationbased data sets; however, in the Swedish study, this was limited by lack of control for the contraceptive pill, and the number of OC cases in the bilateral salpingectomy subgroups is small. Additionally, in high risk women (eg, BRCA carriers), ongoing studies are evaluating the feasibility of premenopausal early salpingectomy and delayed oophorectomy as an ovarian function preserving 2-step method for the prevention of OC.
Some centers have changed clinical protocols to incorporate OBS into practice.
14 Recent guidelines from the American Congress of Obstetricians and Gynecologists 15 and Society of Gynecologic Oncology 16 recommend OBS be considered as an OC prevention strategy while also highlighting the need and importance for further trials to confirm the validity and benefit of this approach. We found that approximately 30% of UK clinicians currently are undertaking this procedure; 89% of them would support a prospective trial. 17 Prospective data on the level of reduction in OC risk after salpingectomy Original Research ajog.org are lacking. Additionally, the presence of residual tubal tissue on the ovarian surface after salpingectomy has not been evaluated prospectively. This could have potential implications for the level of risk reduction. We present data that prospectively reports on the presence of residual microscopic fimbrial tissue on the ovarian surface after salpingectomy.
Methods Patients
Patients who underwent salpingooophorectomy with or without hysterectomy (laparoscopic or laparotomy) for benign indications, early cervical cancer, or low-risk endometrial cancer were included. Patients with other pelvic malignancy, previous bilateral salpingectomy, or bilateral oophorectomy were excluded.
Salpingectomy procedure
The surgical procedure was undertaken in 2 steps within the same operation. Salpingectomy with or without hysterectomy (as indicated) was performed initially. This was followed by bilateral oophorectomy as a second step within the same operation. Thus, overall each patient had the same planned elective surgical procedure. The ovaries and tubes that were removed were sent in separately labelled pots: right tube, left tube, right ovary and left ovary. In some specimens, fallopian tubes remained attached to the uterus. Intraoperative findings were documented with the use of a customized form (Supplementary Figure 1 ). Procedures were undertaken by consultant gynecologists, consultant gynecologic oncologists, and specialist or subspecialty trainees in gynecologic oncology. . 18 This protocol entails lengthwise sectioning of the fimbriated portion of the tube to maximize exposure of the tubal plicae with maximum serial sectioning of no more than 2e3 mm apart. The ovaries were also sectioned serially in their entirety and examined for the presence of any remnant tubal tissue. The uterus, where removed, was assessed in accordance with routine histologic protocol and the surgical indication. Histologic slides that were stained with hematoxylin and eosin were reviewed by both gynecologic pathologists. Confirmation and agreement by both pathologists were obtained in cases in which fimbrial tissues were identified.
Histopathologic examination of fallopian tubes and ovaries
Consecutive patients who fulfilled the inclusion criteria within the Barts Health Cancer Network were identified between October 1, 2015, and January 5, 2016. This was done through close liaison between gynecologic oncology team, benign gynecology consultants who were linked to the cancer network, administrative assistants, and a review of the online surgical diary at Royal London Hospital. Of the 39 consecutive cases that were identified, 25 were finally suitable for analysis. Fourteen were excluded for the following reasons: (1) protocol deviation, with all specimens sent to the pathology laboratory in error in the same single pot (n¼4); (2) Assuming a null hypothesis or gold standard of 1% specimens that have residual tubal tissue, for a power of 80% and a value of .05, the sample size for the identification of 10% specimens with residual tubal tissue is 25. Baseline characteristics were described with the use of descriptive statistics. Chi-square/ Fisher's exact and Mann-Whitney tests were used to evaluate differences between categoric and continuous variables, respectively. Statistical analyses were performed on SPSS software (version 23; IBM Corporation, Armonk, NY).
Results
Forty-one adnexae (9 unilateral and 16 bilateral) from 25 patients were analyzed for histologic presence of tubal fimbrial High-grade serous carcinoma in fimbria that is adherent to ovarian surface High-grade serous carcinoma (red arrow) in 1 of the fimbria (black arrows) that is adherent to the surface of the ovary. Figure 2 . An objective measurement to quantify the residual fimbrial tissue in the 4 cases showed the fimbrial tissue measured: (1) 3Â2Â1 mm; (2) 2Â2Â2 mm; (3) 4Â2.5Â2 mm; (4) 3Â2Â1.5 mm in the 4 cases, respectively. All 4 cases occurred in women who underwent abdominal hysterectomy. There were 2 cases (1 adnexa in each case) in which dense adhesions were encountered intraoperatively. In 1 case, fimbriae were densely adherent to the right ovary; with two-thirds of its fimbrial portions enclosed in adhesions. The other had involvement of the whole tube that included the fimbrial portion being densely adherent to the ovary. However, in both cases, the tubes were separated surgically from the ovaries, and neither ovary showed any residual fimbrial tissue on the ovarian surface. Intraoperatively, there were no adhesions between the tube and ovary in any of the other 23 patients. The fimbriae lay completely separately and were not found to touch the ovary (no fimbria ovarica seen) in any of these 23 patients.
The presence of fimbrial tissue was not significantly affected by the route of surgery (laparoscopic/ laparotomy) or experience of the surgeon. Although all 4 cases with residual fimbrial tissue were performed by laparotomy, this association is not statistically significant (P¼.096); given small numbers, we believe it is probably due to chance. We do not think this relates to surgical technique. One of these 4 cases was performed by a specialist trainee (1/5) under direct supervision and 3 cases (3/20) were performed by experienced consultant gynecologists (P¼1.0).
Comment

Main findings
We found that 16% of the women or 10% of the adnexae had fimbrial tissue implants on the ipsilateral ovarian surface, despite salpingectomy. Moreover, these did not occur in cases with adhesions or any form of adherence of fimbriae/tube to the ovary. The ovaries lay completely separate and well away from the fallopian tubes in these cases. Although surgical removal of an adherent tube (either because of adhesions or fimbria ovarica) may result in residual tubal/fimbrial tissue on the ovarian surface, these findings of implants on nonadherent ovaries in a considerable proportion of women were completely unexpected. This could represent a potential site for ovarian carcinogenesis. To the best of our knowledge, this is the first prospective series to evaluate the presence of residual fimbrial tissue that may remain after salpingectomy. We searched Medline and Embase databases using free text and thesaurus-based search terms: salpingectomy, fimbria, fimbriae, fimbrial tissue, residual tubal tissue, ovary surface, tubal implants, fimbrial implants, uterine tubal mucosa, salpingectomy and ovary. We used 3 strategies: (1) "salpingectomy" AND "fimbria" OR "fimbriae" OR "residual fimbrial tissue" OR "residual tubal tissue" OR "ovary surface"; (2) "tubal implants" OR "fimbrial implants" OR "uterine tubal mucosa" AND "salpingectomy"; and (3) "tubal implants" OR "fimbrial implants" OR "uterine tubal mucosa" AND "ovary." Details of the search strategy are given in the Appendix. Overall 125 abstracts were reviewed by 2 co-authors. No reports that described the presence of fimbrial tissue post salpingectomy were identified (Appendix ).
Strengths and limitations
Our study has several advantages, such as the prospective nature of this work, use of a serial sectioning histopathologic protocol with strict pathologic review by 2 experienced pathologists, and inclusion of both laparoscopic-and laparotomy-based surgical approaches. We excluded cases with benign or malignant adnexal disease, which may have the propensity to increase false-positive findings. All our cases included macroscopic normal-looking tubes and ovaries. A limitation is the small number of cases in our series. Additionally, 4 cases were excluded because of error in transport of histologic specimens. However, this series has sufficient power to detect a !10% incidence of residual 
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fimbrial tissue, which was a level found in this study.
Interpretation/meaning
These findings are of crucial, if not of critical, importance and are hypothesisgenerating. We suggest that clumps of fimbrial tissue may be shed from the fimbrial end of the tubes, some of which implant on the ovarian surface. However, it is also possible that fimbrial tissue adheres to the ovarian surface over repeated ovulatory episodes and then may become detached from the tube. We hypothesize that this residual tissue may also undergo malignant transformation (just like fimbria that was present in the tube) after genotoxic injury over a period of time. The presence of STIC/invasive lesions in the tubal tissue of women with OC that was reported in various series varies from 11e60%. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Our findings support the possible tubal origin of OC, despite the absence of STIC lesions in the tube because malignant transformation could have started in the fimbrial implants on the ovarian surface without involving the rest of the tube. It could also explain a recent finding of some STICs being genomically different to co-existent serous OC and thus metastasize. 31 It also corroborates the hypothesis that OC may arise in cortical inclusion cysts, because the fimbrial tissue found on the surface of the ovary could get incorporated into these cysts and undergo subsequent malignant transformation. 32 Alternatively, the ovarian surface in conjunction with the fimbrial implant may rupture during ovulation and subsequently predispose fimbriae to malignant transformation. Ovarian surface epithelium at junction areas may contain a novel stem-cell niche that is responsible for surface epithelium regeneration and, subsequently, be prone to malignant transformation. 33 We speculate that these fimbrial tissues may also be shed and implant on the peritoneal surface (just as on the ovary); currently, there is no conclusive histologic evidence to support this possibility. However, if true, this could explain the occurrence of primary peritoneal cancer in low-risk women and in 4% BRCA1/ BRCA2 carriers, despite bilateral salpingo-oophorectomy. 34 It may also explain the presence of malignant peritoneal cytologic evidence that is found in some women at risk-reducing surgery without a co-existent invasive cancer/ STIC lesion. 34 The tuboperitoneal junction has been suggested as a likely site for the origin of serous OC, with STICs found at and in the immediate vicinity of the tuboperitoneal junction. 35 Transitional metaplasia is found in up to 26% of tuboperitoneal junctions; it has been proposed that adnexal peritoneum, Fallopian tube epithelium and ovarian surface epithelium should be viewed as a continuous unit. 36 Our data indicate another potential site for STICs that lies outside the tuboperitoneal junction, but within fimbriae that were shed on the ovarian surface. We found fimbrial implants in both premenopausal and postmenopausal women. However, a number of questions remain unanswered, which include the precise mechanism and timing of shedding of fimbrial tissue, the duration for which this tissue may persist on the ovarian surface, and the lead time to malignant transformation after implantation on the ovary. We do not know whether these fimbriae are shed because of hormonal or cell nonautonomous mechanisms that occur predominantly in the premenopausal period with fimbrial tissue subsequently remaining on the ovaries in postmenopausal women or whether this is an active process that also occurs after menopause. These issues must be addressed through future research.
According to the tubal hypothesis, it is fimbrial tissue that is the main cell of origin of HGSC. However, not all HGSCs arise within the tube. 37 Recent genomic analysis of co-existent STIC and serous OC cases indicated STICs were precursors in only 50% of cases. 31 Our findings thus may also help explain the reason that salpingectomy prevents only a proportion of epithelial OC and will not prevent all cases. The issue of undertaking OBS in routine practice or within the context of a welldesigned trial has been debated widely. 38 Early salpingectomy has also been proposed as an alternative initial step (with a delayed oophorectomy in the menopause as a second step) for high-risk women who want to avoid detrimental consequences of premature menopause. 17 Premature menopause itself is associated with a 3.03% increase in cardiovascular death, sexual dysfunction, and osteoporosis. 39 A recent systematic review highlighted the limitation and low-quality of available evidence on level of OC-risk reduction and ovarian function associated with salpingectomy, with the large retrospective studies being limited by indication and detection bias. 40 There has been a lack of clarity on a number of issues, namely the level of risk reduction, the long-term impact of salpingectomy on ovarian function or onset of premature menopause, and the issues of cost-effectiveness of this approach.
Our results suggest that fimbrial tissue persists on the ovarian surface, despite salpingectomy. This could play a role in ovarian carcinogenesis and be one of the reasons that salpingectomy does not prevent all epithelial OC. These data further highlight the importance and need for well-designed prospective trials/research to define more precisely the level of benefit of reduction in OC risk that is obtained from salpingectomy as a surgical prevention strategy. This is required for both the low-and high-risk populations. This is essential to understand the balance of risks and harms of this intervention so that women can make properly informed decisions on whether or not to undergo this procedure. Search terms Three searches were undertaken 1. "salpingectomy" AND "fimbria" OR "fimbriae" OR "residual fimbrial tissue" OR "residual tubal tissue" OR "ovary surface"
2. "tubal implants" OR "fimbrial implants" OR "uterine tubal mucosa" AND "salpingectomy"
3. "tubal implants" OR "fimbrial implants" OR "uterine tubal mucosa" AND "ovary"
Study selection All studies with human participants that investigated the presence of fallopian tube cells/tissue on the ovary, after salpingectomy Data extraction Citation titles and abstracts were reviewed by 2 authors (C.G. and D.C.) Conclusion No studies were identified to have met the search objective. Appendix References
